Ipsen: FOP drug flops
(CercleFinance.com) - Ipsen has announced that, despite a review of palovarotene for the potential treatment of FOP (fibrodysplasia ossificans progressiva), the CHMP of the European Medicines Agency has confirmed the negative opinion it issued last January.
We must now fully concentrate on the regulatory processes underway in other countries, Ipsen said, pointing to positive efficacy results in the phase III MOVE trial.
An ultra-rare disease with an estimated prevalence of 1.36 per million individuals, FOP causes ongoing and permanent abnormal bone formation, leading to progressive loss of mobility and reduced life expectancy.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
We must now fully concentrate on the regulatory processes underway in other countries, Ipsen said, pointing to positive efficacy results in the phase III MOVE trial.
An ultra-rare disease with an estimated prevalence of 1.36 per million individuals, FOP causes ongoing and permanent abnormal bone formation, leading to progressive loss of mobility and reduced life expectancy.
Copyright (c) 2023 CercleFinance.com. All rights reserved.